The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy OnNovember6, 2025,Shanghai, China,CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases,announcedthat the first patient in its Investigator-Initiated Trial (IIT) ofthe base-editing therapyCS-121 targetingAPOC3forchylomicronemia / hypertriglyceridemiahas successfully completed dosing […]